Moderate

Chronic kidney disease (CKD) — staging & conservative (kidney-protective) management

Chronic kidney disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

eGFR <60 mL/min/1.73m2 and/or markers of kidney damage (albuminuria ACR >=3 mg/mmol, haematuria, structural/pathological abnormality) persisting >=3 months. Staged by cause + GFR category (G1 >=90, G2 60-89, G3a 45-59, G3b 30-44, G4 15-29, G5 <15) + albuminuria category (A1 <3, A2 3-30, A3 >30 mg/mmol) — the KDIGO 'GFR/ACR' heat map grades risk of progression, CV death and kidney failure. Conservative management = slow progression (BP, RAS blockade, SGLT2i), treat complications (anaemia, CKD-MBD, acidosis, hyperkalaemia) and reduce CV risk.

Red flags

  • Rapid eGFR decline (>5 mL/min/yr) or active urinary sediment (dysmorphic RBCs/casts) — suspect GN, urgent nephrology
  • Nephrotic-range proteinuria (ACR >220 mg/mmol / PCR >300) or systemic features (rash, haemoptysis, arthralgia) — biopsy-level urgency
  • Resistant hyperkalaemia or acidosis, uraemic encephalopathy/pericarditis, refractory fluid overload — RRT assessment
  • Hypercalcaemia + anaemia + bone pain — exclude myeloma
  • Bilateral small kidneys with anuria or hydronephrosis — obstruction needing decompression

Assessment

Differential diagnosis

  • Acute kidney injury (normal-size kidneys, no anaemia/renal osteodystrophy, recent rise) — vs CKD (small echogenic kidneys, anaemia, hyperphosphataemia)
  • Acute-on-chronic kidney disease
  • Reversible drivers mimicking progression: hypovolaemia, NSAIDs/ACEi, obstruction, contrast
  • Isolated low eGFR from reduced muscle mass (overestimates true impairment)
  • Glomerular disease requiring biopsy (nephrotic-range proteinuria, active sediment, rapid decline)

Investigations

  • U&E, creatinine + eGFR (CKD-EPI 2021, race-free); trend vs old results to confirm chronicity
  • Urine ACR (first-morning) and urine dip/microscopy (haematuria, casts)
  • FBC (normocytic anaemia), ferritin/transferrin saturation
  • Bone profile: calcium, phosphate, PTH, vitamin D (CKD-MBD)
  • Venous bicarbonate (metabolic acidosis), potassium
  • HbA1c, lipids; renal USS (size, symmetry, obstruction, cysts, corticomedullary differentiation)
  • Screen for cause where indicated: immunoglobulins/serum free light chains + urine Bence Jones, ANA/ANCA/anti-GBM/complement, HBV/HCV/HIV, PLA2R

Management

  • Confirm chronicity (>=3 months of reduced eGFR or damage) and exclude reversible/AKI component before labelling
  • Identify and treat the cause; stop nephrotoxins (NSAIDs, aminoglycosides); dose-adjust renally cleared drugs
  • BP target <120 mmHg systolic (standardised office measurement) where tolerated; first-line ACEi or ARB (not both together) titrated to max tolerated dose if ACR >=3 mg/mmol or diabetes
  • Start an SGLT2 inhibitor for eGFR >=20 with ACR >=20-22 mg/mmol (~>=200 mg/g) or type 2 diabetes with CKD, or heart failure — continue even as eGFR falls below 20 unless intolerant/dialysis (KDIGO 2024)
  • Add finerenone in type 2 diabetic CKD with persistent albuminuria despite max RAS blockade if K+ <=4.8 and eGFR >=25 [verify local dose]
  • Treat acidosis (aim bicarbonate >=22), hyperkalaemia, anaemia (iron then ESA when Hb <100 g/L after iron repletion), and CKD-MBD (phosphate binders, control PTH)
  • Lifestyle: salt <5 g/day, moderate protein ~0.8 g/kg/day (avoid high-protein diets), smoking cessation, weight/exercise; 'sick-day rules' — withhold ACEi/ARB, SGLT2i, diuretics, metformin, NSAIDs during dehydrating illness
  • Statin (atorvastatin) for CV risk reduction in essentially all CKD; refer to nephrology if eGFR <30, ACR >70 mg/mmol, rapid decline (>5 mL/min/yr), refractory complications, or suspected genetic/inflammatory cause; plan access/transplant work-up as G4-5 approaches

Drugs & doses

Ramipril 1.25-2.5 mg PO once daily, titrate to 10 mg/day as tolerated (recheck U&E + K+ at 1-2 weeks; accept creatinine rise up to ~30%) [verify local dose]
Losartan 50 mg PO once daily up to 100 mg/day (ARB alternative if ACEi-intolerant) [verify local dose]
Dapagliflozin 10 mg PO once daily (kidney/CV protection in CKD +/- diabetes; hold during acute dehydrating illness)
Empagliflozin 10 mg PO once daily (alternative SGLT2i)
Finerenone 10-20 mg PO once daily (nonsteroidal MRA; diabetic CKD, monitor K+) [verify local dose]
Atorvastatin 20 mg PO once daily (CV risk reduction)
Sodium bicarbonate 500 mg-1 g PO two-three times daily, titrate to venous bicarbonate >=22 mmol/L [verify local dose]
Oral iron (ferrous fumarate 210 mg PO once-twice daily) or IV iron if oral poorly tolerated/ineffective; ESA (e.g. darbepoetin) once iron-replete and Hb <100 g/L, target Hb 100-115 g/L [verify local dose]
Calcium-free phosphate binder (sevelamer 800 mg PO three times daily with meals) for hyperphosphataemia [verify local dose]

Disposition

Mostly outpatient/primary-care managed with nephrology co-management per referral criteria (eGFR <30, ACR >70 mg/mmol, rapid decline, refractory complications). Admit for symptomatic uraemia, refractory hyperkalaemia/acidosis, fluid overload or newly dialysis-requiring failure. Plan RRT modality/access and transplant work-up well before G5.

Complications & pitfalls

  • Progression to kidney failure (G5) requiring dialysis/transplant
  • Accelerated cardiovascular disease (leading cause of death)
  • Renal anaemia; CKD-mineral bone disorder (secondary hyperparathyroidism, vascular calcification, fractures)
  • Hyperkalaemia and metabolic acidosis
  • Volume overload, uncontrolled hypertension, drug accumulation/toxicity

Exam pearls

  • KDIGO 2024 CKD guideline: SGLT2i is now foundational (diabetic and non-diabetic albuminuric CKD) alongside RAS blockade, statin and BP control — the '4 pillars' of kidney protection.
  • An eGFR drop up to ~30% and a small K+ rise after starting ACEi/ARB or SGLT2i is expected and not a reason to stop — recheck and continue.
  • Give every CKD patient written 'sick-day rules' and a nephrotoxin-avoidance list; most 'progression' presenting acutely is superimposed reversible AKI.
  • Use the ACR, not just eGFR, to stratify risk and refer — a G3a/A3 patient outranks a G3b/A1 patient for renal and CV risk.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.